Competitive landscape
Drugs aimed at the same indication, from approved to preclinical.
9 drugs for “Metastatic Non Small Cell Lung Cancer”
Approved 1
- SelumetinibASTRAZENECA PLCLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Phase 3 7
- CeralasertibASTRAZENECA PLCAdvanced or Metastatic Non-Small Cell Lung Cancer
- Eftilagimod alfaIMMUTEP LtdAdvanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- FirmonertinibArriVent BioPharma, Inc.Metastatic Non-Small-Cell Lung Cancer
- FurmonertinibArriVent BioPharma, Inc.Metastatic Non-Small Cell Lung Cancer
- MRTX849Mirati Therapeutics, Inc.Metastatic Non Small Cell Lung Cancer
- TAK-788TAKEDA PHARMACEUTICAL CO LTDAdvanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
- VolrustomigASTRAZENECA PLCMetastatic Non-small Cell Lung Cancer
Phase 2/3 1
- BMS-986504BRISTOL MYERS SQUIBB COMetastatic Non-small Cell Lung Cancer With MTAP Deletion
Drugs whose recorded indications name this term, by development stage. Indications come from registries and labels, so a drug can appear under related terms.